Decoy Therapeutics Amends 10-K to Disclose High Audit Costs and Executive Compensation Details
DCOY is trading near its 52-week low of $5.15 (7.6% above the low) on light trading volume (0.1× avg).
Summary
Decoy Therapeutics filed an amended 10-K to include omitted governance and compensation details, revealing a significant increase in audit fees for 2025 and a compliance lapse.
Key Events · Corporate Governance and Compliance · DCOY
-
Compliance Amendment Filed
The company filed a 10-K/A to include omitted Part III information (Items 10-14) from its original 2025 Annual Report, due to the inability to file a definitive proxy statement within the required timeframe.
-
Significant Increase in Audit Fees
Audit fees for fiscal year 2025 surged to $908,179, a substantial increase from $255,038 in 2024, representing a considerable expense for the micro-cap company.
-
Executive Compensation and Ownership Disclosed
The filing details executive compensation for 2025, including a $225,000 transaction bonus for the CFO, and reports that all executive officers and directors beneficially own 1.7% of the outstanding common stock.
-
Related Party Debt Conversion
Outstanding demand notes from an officer/founder and a family member, totaling approximately $270,000 (principal plus accrued interest), are slated for exchange into Series B Preferred Stock.
Analysis · DCOY · Life Sciences
This 10-K/A filing is a compliance amendment to include previously omitted Part III information (Items 10-14) from the company's Annual Report for fiscal year 2025. The omission occurred because the company will not file a definitive proxy statement within the required 120-day period, indicating a lapse in corporate governance. A key disclosure within this amendment is the substantial increase in audit fees, rising from $255,038 in 2024 to $908,179 in 2025. This represents a significant operational expense for a company that previously reported substantial doubt about its ability to continue as a going concern, further highlighting its financial challenges. The filing also details executive compensation, including a $225,000 transaction bonus for the CFO, and beneficial ownership, with all executive officers and directors collectively owning a small percentage of the company.
At the time of this filing, DCOY was trading at $5.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $5.15 to $415.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.